Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment
Abstract It is long recognized that cancer cells display increased glucose uptake and metabolism. In a rate-limiting step for glucose metabolism, the glucose transporter (GLUT) proteins facilitate glucose uptake across the plasma membrane. Fourteen members of the GLUT protein family have been identi...
Gespeichert in:
| Veröffentlicht in: | Metabolism, clinical and experimental clinical and experimental, 2016-02, Vol.65 (2), p.124-139 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 139 |
|---|---|
| container_issue | 2 |
| container_start_page | 124 |
| container_title | Metabolism, clinical and experimental |
| container_volume | 65 |
| creator | Barron, Carly C Bilan, Philip J Tsakiridis, Theodoros Tsiani, Evangelia |
| description | Abstract It is long recognized that cancer cells display increased glucose uptake and metabolism. In a rate-limiting step for glucose metabolism, the glucose transporter (GLUT) proteins facilitate glucose uptake across the plasma membrane. Fourteen members of the GLUT protein family have been identified in humans. This review describes the major characteristics of each member of the GLUT family and highlights evidence of abnormal expression in tumors and cancer cells. The regulation of GLUTs by key proliferation and pro-survival pathways including the phosphatidylinositol 3-kinase (PI3K)-Akt, hypoxia-inducible factor-1 (HIF-1), Ras, c-Myc and p53 pathways is discussed. The clinical utility of GLUT expression in cancer has been recognized and evidence regarding the use of GLUTs as prognostic or predictive biomarkers is presented. GLUTs represent attractive targets for cancer therapy and this review summarizes recent studies in which GLUT1, GLUT3, GLUT5 and others are inhibited to decrease cancer growth. |
| doi_str_mv | 10.1016/j.metabol.2015.10.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760859089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0026049515002991</els_id><sourcerecordid>1760859089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-b432ed14c21e85e8bd65e0e5782e839b1bd94d48570643217a3f5b912dca7bb13</originalsourceid><addsrcrecordid>eNqFkc9vFCEUx4nR2G31T9DM0YOzAjP88mBjGqtNmnhQj4Yw8LZhZWAFpkn_e5ns2oMXT5CXz_c9-DyEXhG8JZjwd_vtDNVMKWwpJqzVthiLJ2hD2EB7yTF-ijYYU97jUbEzdF7KHjdCSP4cnVEuxKAGtkE_r431wVdT_T10d2GxqUBXs4nlkHKFXN53N_MheNuIFEu3S7mzJlrInYMKdq2-7Q453cVUfOlMdC0Ops4Q6wv0bGdCgZen8wL9uP70_epLf_v1883Vx9vejpLXfhoHCo6MlhKQDOTkOAMMTEgKclATmZwa3SiZwLyhRJhhxyZFqLNGTBMZLtCbY9_2jt8LlKpnXyyEYCKkpWgiOJZMYakayo6ozamUDDt9yH42-UETrFezeq9PZvVqdi03by33-jRimWZwj6m_KhtweQSgffTeQ9bFemiinM9Nk3bJ_3fEh3862OBjMx9-wQOUfVpybBY10YVqrL-t6123S1i7KUWGP3hgos4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760859089</pqid></control><display><type>article</type><title>Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Barron, Carly C ; Bilan, Philip J ; Tsakiridis, Theodoros ; Tsiani, Evangelia</creator><creatorcontrib>Barron, Carly C ; Bilan, Philip J ; Tsakiridis, Theodoros ; Tsiani, Evangelia</creatorcontrib><description>Abstract It is long recognized that cancer cells display increased glucose uptake and metabolism. In a rate-limiting step for glucose metabolism, the glucose transporter (GLUT) proteins facilitate glucose uptake across the plasma membrane. Fourteen members of the GLUT protein family have been identified in humans. This review describes the major characteristics of each member of the GLUT family and highlights evidence of abnormal expression in tumors and cancer cells. The regulation of GLUTs by key proliferation and pro-survival pathways including the phosphatidylinositol 3-kinase (PI3K)-Akt, hypoxia-inducible factor-1 (HIF-1), Ras, c-Myc and p53 pathways is discussed. The clinical utility of GLUT expression in cancer has been recognized and evidence regarding the use of GLUTs as prognostic or predictive biomarkers is presented. GLUTs represent attractive targets for cancer therapy and this review summarizes recent studies in which GLUT1, GLUT3, GLUT5 and others are inhibited to decrease cancer growth.</description><identifier>ISSN: 0026-0495</identifier><identifier>EISSN: 1532-8600</identifier><identifier>DOI: 10.1016/j.metabol.2015.10.007</identifier><identifier>PMID: 26773935</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Cancer metabolism ; Endocrinology & Metabolism ; Fluorodeoxyglucose F18 ; Glucose Transport Proteins, Facilitative - antagonists & inhibitors ; Glucose Transport Proteins, Facilitative - classification ; Glucose Transport Proteins, Facilitative - physiology ; Glucose transporter ; GLUT ; Humans ; Neoplasms - diagnosis ; Neoplasms - therapy ; Prognosis ; SLC2 ; Warburg effect</subject><ispartof>Metabolism, clinical and experimental, 2016-02, Vol.65 (2), p.124-139</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-b432ed14c21e85e8bd65e0e5782e839b1bd94d48570643217a3f5b912dca7bb13</citedby><cites>FETCH-LOGICAL-c486t-b432ed14c21e85e8bd65e0e5782e839b1bd94d48570643217a3f5b912dca7bb13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.metabol.2015.10.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26773935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barron, Carly C</creatorcontrib><creatorcontrib>Bilan, Philip J</creatorcontrib><creatorcontrib>Tsakiridis, Theodoros</creatorcontrib><creatorcontrib>Tsiani, Evangelia</creatorcontrib><title>Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment</title><title>Metabolism, clinical and experimental</title><addtitle>Metabolism</addtitle><description>Abstract It is long recognized that cancer cells display increased glucose uptake and metabolism. In a rate-limiting step for glucose metabolism, the glucose transporter (GLUT) proteins facilitate glucose uptake across the plasma membrane. Fourteen members of the GLUT protein family have been identified in humans. This review describes the major characteristics of each member of the GLUT family and highlights evidence of abnormal expression in tumors and cancer cells. The regulation of GLUTs by key proliferation and pro-survival pathways including the phosphatidylinositol 3-kinase (PI3K)-Akt, hypoxia-inducible factor-1 (HIF-1), Ras, c-Myc and p53 pathways is discussed. The clinical utility of GLUT expression in cancer has been recognized and evidence regarding the use of GLUTs as prognostic or predictive biomarkers is presented. GLUTs represent attractive targets for cancer therapy and this review summarizes recent studies in which GLUT1, GLUT3, GLUT5 and others are inhibited to decrease cancer growth.</description><subject>Animals</subject><subject>Cancer metabolism</subject><subject>Endocrinology & Metabolism</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glucose Transport Proteins, Facilitative - antagonists & inhibitors</subject><subject>Glucose Transport Proteins, Facilitative - classification</subject><subject>Glucose Transport Proteins, Facilitative - physiology</subject><subject>Glucose transporter</subject><subject>GLUT</subject><subject>Humans</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - therapy</subject><subject>Prognosis</subject><subject>SLC2</subject><subject>Warburg effect</subject><issn>0026-0495</issn><issn>1532-8600</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9vFCEUx4nR2G31T9DM0YOzAjP88mBjGqtNmnhQj4Yw8LZhZWAFpkn_e5ns2oMXT5CXz_c9-DyEXhG8JZjwd_vtDNVMKWwpJqzVthiLJ2hD2EB7yTF-ijYYU97jUbEzdF7KHjdCSP4cnVEuxKAGtkE_r431wVdT_T10d2GxqUBXs4nlkHKFXN53N_MheNuIFEu3S7mzJlrInYMKdq2-7Q453cVUfOlMdC0Ops4Q6wv0bGdCgZen8wL9uP70_epLf_v1883Vx9vejpLXfhoHCo6MlhKQDOTkOAMMTEgKclATmZwa3SiZwLyhRJhhxyZFqLNGTBMZLtCbY9_2jt8LlKpnXyyEYCKkpWgiOJZMYakayo6ozamUDDt9yH42-UETrFezeq9PZvVqdi03by33-jRimWZwj6m_KhtweQSgffTeQ9bFemiinM9Nk3bJ_3fEh3862OBjMx9-wQOUfVpybBY10YVqrL-t6123S1i7KUWGP3hgos4</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Barron, Carly C</creator><creator>Bilan, Philip J</creator><creator>Tsakiridis, Theodoros</creator><creator>Tsiani, Evangelia</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160201</creationdate><title>Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment</title><author>Barron, Carly C ; Bilan, Philip J ; Tsakiridis, Theodoros ; Tsiani, Evangelia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-b432ed14c21e85e8bd65e0e5782e839b1bd94d48570643217a3f5b912dca7bb13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Cancer metabolism</topic><topic>Endocrinology & Metabolism</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glucose Transport Proteins, Facilitative - antagonists & inhibitors</topic><topic>Glucose Transport Proteins, Facilitative - classification</topic><topic>Glucose Transport Proteins, Facilitative - physiology</topic><topic>Glucose transporter</topic><topic>GLUT</topic><topic>Humans</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - therapy</topic><topic>Prognosis</topic><topic>SLC2</topic><topic>Warburg effect</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barron, Carly C</creatorcontrib><creatorcontrib>Bilan, Philip J</creatorcontrib><creatorcontrib>Tsakiridis, Theodoros</creatorcontrib><creatorcontrib>Tsiani, Evangelia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolism, clinical and experimental</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barron, Carly C</au><au>Bilan, Philip J</au><au>Tsakiridis, Theodoros</au><au>Tsiani, Evangelia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment</atitle><jtitle>Metabolism, clinical and experimental</jtitle><addtitle>Metabolism</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>65</volume><issue>2</issue><spage>124</spage><epage>139</epage><pages>124-139</pages><issn>0026-0495</issn><eissn>1532-8600</eissn><abstract>Abstract It is long recognized that cancer cells display increased glucose uptake and metabolism. In a rate-limiting step for glucose metabolism, the glucose transporter (GLUT) proteins facilitate glucose uptake across the plasma membrane. Fourteen members of the GLUT protein family have been identified in humans. This review describes the major characteristics of each member of the GLUT family and highlights evidence of abnormal expression in tumors and cancer cells. The regulation of GLUTs by key proliferation and pro-survival pathways including the phosphatidylinositol 3-kinase (PI3K)-Akt, hypoxia-inducible factor-1 (HIF-1), Ras, c-Myc and p53 pathways is discussed. The clinical utility of GLUT expression in cancer has been recognized and evidence regarding the use of GLUTs as prognostic or predictive biomarkers is presented. GLUTs represent attractive targets for cancer therapy and this review summarizes recent studies in which GLUT1, GLUT3, GLUT5 and others are inhibited to decrease cancer growth.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26773935</pmid><doi>10.1016/j.metabol.2015.10.007</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0026-0495 |
| ispartof | Metabolism, clinical and experimental, 2016-02, Vol.65 (2), p.124-139 |
| issn | 0026-0495 1532-8600 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1760859089 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Cancer metabolism Endocrinology & Metabolism Fluorodeoxyglucose F18 Glucose Transport Proteins, Facilitative - antagonists & inhibitors Glucose Transport Proteins, Facilitative - classification Glucose Transport Proteins, Facilitative - physiology Glucose transporter GLUT Humans Neoplasms - diagnosis Neoplasms - therapy Prognosis SLC2 Warburg effect |
| title | Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A47%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Facilitative%20glucose%20transporters:%20Implications%20for%20cancer%20detection,%20prognosis%20and%20treatment&rft.jtitle=Metabolism,%20clinical%20and%20experimental&rft.au=Barron,%20Carly%20C&rft.date=2016-02-01&rft.volume=65&rft.issue=2&rft.spage=124&rft.epage=139&rft.pages=124-139&rft.issn=0026-0495&rft.eissn=1532-8600&rft_id=info:doi/10.1016/j.metabol.2015.10.007&rft_dat=%3Cproquest_cross%3E1760859089%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760859089&rft_id=info:pmid/26773935&rft_els_id=1_s2_0_S0026049515002991&rfr_iscdi=true |